BridgeMD
The role of intra-abdominal pressure and point of care ultrasound to guide decongestive therapy in Heart Failure (ABDOPOCUS-HF)
EU CTIS ID: 2024-512901-22-00
What this study is testing
To evaluate the complete resolution of congestion (ADVOR scale) after the first 72 hours of intravenous diuretic treatment on the hospital ward, between the standard treatment group and the intervention group (intra-abdominal pressure and ultrasound)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Men or women over 18 years of age
- Diagnosis of HF based on the latest HF guidelines published in 2022
- NT-proBNP > 1000 pg/mL or BNP > 250 pg/mL
- Bladder catheterization in order to perform intra-abdominal pressure measurement
- Intravascular or mixed pattern of congestion, defined as the presence of one or more clinical signs of congestion (edema, ascites and/or pleural effusion)
- Signature of the informed consent
You likely can't join if
- Patient with stay in the internal medicine department > 24 hours
- Systolic blood pressure at admission < 100 mmHg
- Heart rate at admission > 170 beats per minute (bpm)
- Cardiogenic shock
- Acute myocardial ischemia
- Patients receiving renal replacement therapy (ultrafiltration or peritoneal dialysis).
See the full eligibility criteria
- Men or women over 18 years of age
- Diagnosis of HF based on the latest HF guidelines published in 2022
- NT-proBNP > 1000 pg/mL or BNP > 250 pg/mL
- Bladder catheterization in order to perform intra-abdominal pressure measurement
- Intravascular or mixed pattern of congestion, defined as the presence of one or more clinical signs of congestion (edema, ascites and/or pleural effusion)
- Signature of the informed consent
- Patient with stay in the internal medicine department > 24 hours
- Systolic blood pressure at admission < 100 mmHg
- Heart rate at admission > 170 beats per minute (bpm)
- Cardiogenic shock
- Acute myocardial ischemia
- Patients receiving renal replacement therapy (ultrafiltration or peritoneal dialysis).
- Patients whose origin is the Intensive Care Unit
- Renal transplant recipients
- Serum hemoglobin < 9 g/dL
- Pregnancy or lactation
- Previous history of hypersensitivity to hydrochlorothiazide or furosemide.
- Patients with recent cardiac surgery (last year) or cardiac transplant recipients
- Need for inotropic support to maintain adequate cardiac and/or renal output
- Absence of sufficient clinical congestion (ADVOR score = 0 at the time of randomization)
- Patient refusal to participate in the clinical trial
- Inability or contraindication to bladder catheterization
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.